PI Healthsciences, a provider of specialty chemistry serving global pharmaceutical innovators, agreed to acquire Archimica, a pharmaceutical fine chemicals company that combines chemical manufacturing with pharmaceutical commercialization, form Livia Group, an independent industrial holding. Financial terms were not disclosed. “We are excited about this acquisition as it marks a solid and accelerated beginning of PI’s journey in the pharma space. Our unique ability to build concrete offerings from abstract situations and leverage our capabilities across complex chemistries in the value chain will once again help create a differentiated value proposition for our stakeholders. This acquisition aligns with PI’s approach of working with global innovators and being at the forefront of innovation, science, technology and human ingenuity to create transformative solutions in life sciences with the purpose of reimagining a healthier planet. We are excited to welcome the talented team from Archimica to the PI family. We look forward to deploying all our combined expertise towards unique value delivery for our customers. I compliment PI’s leadership team and external advisors in fructifying this strategic opportunity”, Mayank Singhal, PI Industries Vice Chairperson & Managing Director.